Unity Biotechnology (NASDAQ:UBX) is scheduled to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Unity Biotechnology to post earnings of ($0.44) per share for the quarter.
Unity Biotechnology (NASDAQ:UBX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. On average, analysts expect Unity Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of UBX opened at $6.67 on Tuesday. Unity Biotechnology has a 52 week low of $6.42 and a 52 week high of $24.56. The firm has a market cap of $291.77 million, a price-to-earnings ratio of -2.63 and a beta of -0.28. The firm has a 50-day moving average of $8.12.
About Unity Biotechnology
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
Further Reading: Quick Ratio
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.